M5717 60 mg + Pyronaridine + Atovaquone-Proguanil + M5717 200 mg + M5717 660mg

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Malaria Infection

Conditions

Malaria Infection

Trial Timeline

Nov 28, 2023 → Dec 29, 2024

NCT ID

NCT05974267

About M5717 60 mg + Pyronaridine + Atovaquone-Proguanil + M5717 200 mg + M5717 660mg

M5717 60 mg + Pyronaridine + Atovaquone-Proguanil + M5717 200 mg + M5717 660mg is a phase 2 stage product being developed by Merck for Malaria Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT05974267. Target conditions include Malaria Infection.

What happened to similar drugs?

11 of 19 similar drugs in Malaria Infection were approved

Approved (11) Terminated (1) Active (8)

✅COA566NovartisApproved

✅Artesunate-mefloquine + Atovaquone-proguanil + Artemether-lumefantrineNovartisApproved

✅Co-artemetherNovartisApproved

✅Artemether-lumefantrineNovartisApproved

✅Flavoquine®, Camoquin® Suspension + Flavoquine®, Camoquin® SuspensionPfizerApproved

✅Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination) + Coartem® (arthemether+ lumefantrine)SanofiApproved

✅Artesunate + Artesunate + Sulfadoxine-Pyrimethamine + arthemether + lumefantrineSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05974267	Phase 2	Completed	Nov 28, 2023	Dec 29, 2024	Malaria Infection

Competing Products

20 competing products in Malaria Infection

See all competitors

Product	Company	Stage	Hype Score
SAR97276A	Sanofi	Phase 2	27
SJ733 + Cobicistat	Eisai	Phase 1	29
(+)-SJ000557733 (SJ733)	Eisai	Phase 2	35
E1018 + Placebo	Eisai	Phase 1	36
ZY19489 + Ferroquine (FQ) + Placebo	Zydus Lifesciences	Phase 1	36
ZY19489 Capsule + Placebo Capsule	Zydus Lifesciences	Phase 1	29
M5717 330 mg + M5717 500 mg + M5717 660 mg + Pyronaridine 360 mg + Pyronaridine 360 mg + Pyronaridine 540 mg + Pyronaridine 720 mg	Merck	Phase 2	35
MK-7602 + Artemether/lumefantrine + Primaquine + Artesunate + Atovaquone/proguanil	Merck	Phase 1	29
KLU156 + Coartem	Novartis	Phase 3	40
KAF156	Novartis	Phase 2	35
KAE609 + IV Artesunate + Coartem	Novartis	Phase 2	35
KAE609	Novartis	Phase 2	35
artemether:lumefantrine (2.5 mg:30 mg)	Novartis	Phase 2/3	30
Artemether-lumefantrine (COA566)	Novartis	Phase 2/3	38
INE963	Novartis	Phase 2	35
Ganaplacide + Itraconazole	Novartis	Phase 1	29
KAE609 + Piperaquine Phosphate	Novartis	Phase 1	21
Artemether-lumefantrine	Novartis	Phase 3	40
KAE609 + SoC (Coartem) + KLU156	Novartis	Phase 2	35
KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation	Novartis	Phase 2	35